GDC-0927 R-form

CAS No. 1642297-53-7

GDC-0927 R-form( GDC0927 R-form )

Catalog No. M12491 CAS No. 1642297-53-7

GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    GDC-0927 R-form
  • Note
    Research use only, not for human use.
  • Brief Description
    GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD).
  • Description
    GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) for treatment of metastatic hormone receptor-positive/HER2-negative breast cancer.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    GDC0927 R-form
  • Pathway
    Endocrinology/Hormones
  • Target
    Estrogen Receptor/ERR
  • Recptor
    Estrogen Receptor/ERR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1642297-53-7
  • Formula Weight
    461.533
  • Molecular Formula
    C28H28FNO4
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (108.34 mM)
  • SMILES
    ——
  • Chemical Name
    (R)-2-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-3-(3-hydroxyphenyl)-4-methyl-2H-chromen-6-ol

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • XR 5944

    XR 5944 is an antitumor compound that targets DNA, is a topoisomerase inhibitor, inhibits ER activity, and can be used to study colon and lung cancer.

  • Melibiose

    Melibiose is a reducing disaccharide formed by an alpha-1, 6 linkage between galactose and glucose (D-Gal-α(1→6)-D-Glc).

  • Acolbifene

    Acolbifene is a selective antagonist of estrogen receptors with IC50s of 2 nM and 0.4 nM for estradiol-induced transcriptional activity of ERα and ERβ. Acolbifene shows an anticarcinogenic property.